Human immunoglobulin for intravenous injection (IVIG) has the capacity of proving passive immunity and anti-inflammatory, immunomodulatory effect which results in better treatment and prognosis of severe infections such as COVID-19. The IgG antibodies extracted from recovered patients of COVID-19 are expected to boost the immune response in newly infected patients, leading to a reduction in the treatment duration. Hence, the combination of the immune IgG antibodies as human immunoglobulin for intravenous injection (IVIG) with antiviral drugs can offer short-term and medium-term solutions against COVID-19. Hence, the COVID-19 outbreak is expected to increase demand for human immunoglobulin (pH4) for intravenous injection which is expected to boost the growth of global human immunoglobulin (Ph4) for intravenous injection market.
Market Dynamics
The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to enhance their market presence is expected to propel the market growth during the forecast period. For instance, in January 2020, ADMA Biologics, Inc., a manufacturer, and distributor of plasma-derived biologics, entered a 5-year manufacturing and supply agreement with an undisclosed partner to produce and sell plasma-derived intermediate fractions from ADMA’s Immune Globulin (IG) manufacturing process. Under this agreement, ADMA Biologics, Inc. will maximize the revenue per liter of plasma fractionated in its plant by selling the fractioned plasma to a third party to develop their therapeutic products under their own licensed manufacturing processes.
Key features of the study:
- This report provides in-depth analysis of the global human immunoglobulin (pH4) for intravenous injection market and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global human immunoglobulin (pH4) for intravenous injection market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring, Bayer AG, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Inc, China Biologic Products, Inc., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical Group Co., Ltd., ADMA Biologics, Inc., and Sinopharm Group Co., Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, disease indication up-gradation, market expansion, and marketing tactics
- The global human immunoglobulin (pH4) for intravenous injection market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human immunoglobulin (pH4) for intravenous injection market
Detailed Segmentation:
- Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Type:
- Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Disease Indication :
- COVID-19
- Primary Immunodeficiency Disease
- Immune-mediated Thrombocytopenia
- Kawasaki Disease
- B Chronic lymphocytic Leukemia(B-CLL)
- Others
- Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Region:
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Takeda Pharmaceutical Company Limited
- Baxter
- CSL
- Bayer AG
- Grifols, S.A
- Octapharma Brasil Ltda
- Shanghai RAAS Blood Products Co Ltd
- Hualan Biological Engineering, Inc
- Top Bio Group Co, Ltd (A subsidiary of China Biologic Products Holdings, Inc)
- China Resources Boya Bio-pharmaceutical Group Co Ltd
- ADMA Biologics, Inc
- Sinopharm Group Co. Ltd
